Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal renal function or severe (eGFR \<30 mL/min/1.73 m2) renal impairment to evaluate the effect of renal impairment on the pharmacokinetics (PK) of TD 4208.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

NCT06592482

Renal Impairment

COMPLETED PHASE1

A Multi-Center, Open-Label Study

NCT01468259

Renal Disease End Stage Renal Disease

WITHDRAWN PHASE1

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

NCT05541159

Renal Impairment

WITHDRAWN PHASE1

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

NCT03189498

Renal Insufficiency

COMPLETED PHASE1

A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)

NCT06814119

Healthy Renal Impairment

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renal Impairment

Eight subjects with Severe Renal Impairment (eGFR \<30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.

Group Type EXPERIMENTAL

TD-4208

Intervention Type DRUG

A single inhaled dose of TD 4208 (175 mcg)

Normal Renal Function

Eight healthy participants matched to participants with severe renal impairment.

Intervention is TD-4208, 175mcg, inhaled, single dose.

Group Type EXPERIMENTAL

TD-4208

Intervention Type DRUG

A single inhaled dose of TD 4208 (175 mcg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TD-4208

A single inhaled dose of TD 4208 (175 mcg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

revefenacin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For renal impairment group:

* Subject has severe renal impairment (eGFR \<30 mL/min/1.73 m2)

For normal renal function group:

* Subject is in good health

Exclusion Criteria

* Women who are pregnant, lactating, breastfeeding, or planning to become pregnant during the study.
* Subject has received an investigational drug (or medical device) within 30 days
* Subject who, for any reason, is deemed by the investigator to be inappropriate for this study; or has any condition that would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes